QDEL — QuidelOrtho Corporation

QDEL Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $724 million, a 2% increase year-over-year (YoY). Excluding COVID and Donor Screening, revenue grew by 7%.
• Full Year Revenue: $2.73 billion, meeting 2025 guidance. Non-respiratory revenue grew 5% YoY.
• Labs Business Growth: 7% in Q4 and 6% for the full year, representing 55% of total revenue.
• Respiratory Revenue: Declined 14% in Q4 and 20% for the full year due to reduced COVID testing.
• Adjusted EBITDA: $153 million in Q4 with a margin of 21%. Full year adjusted EBITDA was $597 million, a 240 basis point improvement YoY, with a margin of 22%.
• Adjusted Diluted EPS: $0.46 for Q4 and $2.12 for the full year, a 15% increase YoY.
• Cash Flow: Generated $87 million in free cash flow in Q4; full year free cash flow was $77 million, with recurring free cash flow at $100 million (17% of adjusted EBITDA).

2. Strategic Updates and Business Highlights

• Cost Savings Initiatives: Achieved $140 million in cost savings, improving operational efficiency and financial flexibility.
• R&D Progress: FDA clearance received for high-sensitivity troponin assay and ID MTS Direct Antiglobulin Test Card, enhancing product offerings.
• Leadership Transition: CFO Joe Busky announced retirement effective June 2026, with a search for a successor underway.
• Focus Areas: Prioritizing customer-centric strategies, operational performance, and product development to drive long-term growth.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected between $2.7 billion and $2.9 billion, with a similar quarterly revenue phasing as in 2025.
• Adjusted EBITDA: Anticipated between $630 million and $670 million, with an adjusted EBITDA margin of approximately 23.3%.
• Free Cash Flow: Projected between $120 million and $160 million, factoring in one-time cash uses associated with facility consolidation.
• Growth Expectations: Labs business to continue mid-single-digit growth; immunohematology to grow in low single digits; respiratory revenue expected to remain flat.

4. Bad News, Challenges, or Points of Concern

• Respiratory Revenue Decline: Significant drop in revenue from COVID-19 testing, impacting overall growth.
• Cash Flow Conversion: Actual cash flow conversion fell short of targets, with only 17% of adjusted EBITDA converted to free cash flow, attributed to timing issues in cash collections.
• Goodwill Impairment: A significant non-cash goodwill charge of $701 million recorded in Q3, reflecting post-pandemic market valuations.
• Interest Expense: Expected to rise in 2026, impacting profitability.

5. Notable Q&A Insights

• Free Cash Flow Concerns: Management acknowledged cash flow timing issues that caused lower-than-expected conversion in Q4, with expectations for improvement in 2026.
• Sustainability of Labs Growth: Management expressed confidence in sustaining growth in the Labs business, driven by strong market positions and opportunities in immunoassay.
• China Market Risks: Potential nationalized value-based procurement program could impact revenue, but details remain unclear.
• LEX Diagnostics Platform: Anticipated FDA clearance is progressing, with expectations for commercialization to follow.
• Direct Procurement Initiatives: Expected to improve margins over time, but benefits may not be fully realized until 2027.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and challenges faced by QuidelOrtho as discussed in the Q4 2025 earnings call.